Date | Price Target | Rating | Analyst |
---|---|---|---|
9/5/2024 | Neutral | BTIG Research | |
6/24/2024 | Hold | Argus | |
5/30/2024 | $54.00 | Sell | Goldman |
BTIG Research initiated coverage of Solventum Corporation with a rating of Neutral
Argus initiated coverage of Solventum Corporation with a rating of Hold
Goldman initiated coverage of Solventum Corporation with a rating of Sell and set a new price target of $54.00
IRANNOTICE - Solventum Corp (0001964738) (Filer)
10-Q - Solventum Corp (0001964738) (Filer)
8-K - Solventum Corp (0001964738) (Filer)
8-K - Solventum Corp (0001964738) (Filer)
Separation activities and business continuity on trackReported sales increased 0.2% to $2.081 billion; organic sales increased 1.3%GAAP Earnings Per Share (EPS) of $0.51; adjusted EPS1 of $1.56Generated $355 million in cash from operations; free cash flow1 of $297 millionRaises full-year 2024 organic sales growth and adjusted EPS guidanceST. PAUL, Minn., Aug. 8, 2024 /PRNewswire/ -- Solventum (NYSE:SOLV) today reported financial results as a stand-alone company for the second quarter ended June 30, 2024. "As we continue to execute a complex transformation, we're encouraged by
ST. PAUL, Minn., July 16, 2024 /PRNewswire/ -- Solventum (NYSE:SOLV) will release its second quarter 2024 financial results on Thursday, August 8, 2024 after the U.S. financial markets close. The company will also host a conference call that day at 4:30 p.m. Eastern Time to discuss its second quarter financial results and provide an update on its business. The conference call can be accessed via audio webcast at investors.solventum.com or by dialing (800) 715-9871 within the U.S. or +1 (646) 307-1963 for international callers, using the conference ID 6342275. A replay of the w
4 - Solventum Corp (0001964738) (Issuer)
4 - Solventum Corp (0001964738) (Issuer)
4 - Solventum Corp (0001964738) (Issuer)
4 - Solventum Corp (0001964738) (Issuer)
4 - Solventum Corp (0001964738) (Issuer)
4 - Solventum Corp (0001964738) (Issuer)
4 - Solventum Corp (0001964738) (Issuer)
4 - Solventum Corp (0001964738) (Issuer)
4 - Solventum Corp (0001964738) (Issuer)
4 - Solventum Corp (0001964738) (Issuer)
New V.A.C.® Peel and Place Dressing makes negative pressure wound therapy more accessible, less painful ST. PAUL, Minn., Sept. 10, 2024 /PRNewswire/ -- Solventum (NYSE:SOLV) today announced the launch of the V.A.C.® Peel and Place Dressing, an integrated dressing and drape that can be applied in less than two minutesi and worn by patients for up to seven daysii. Traditional dressings for negative pressure wound therapy typically take more than twice as long to apply, require a multi-step process of measuring and cutting separate foam and adhesive components, and may need to be
ST. PAUL, Minn., Aug. 28, 2024 /PRNewswire/ -- Solventum (NYSE:SOLV) executives plan to participate in the following investor conferences: 2024 Wells Fargo Healthcare Conference in Everett, MA on Wednesday, September 4, 2024 at 11:00 a.m. ET.Morgan Stanley 22nd Annual Global Healthcare Conference in New York, NY on Thursday, September 5, 2024 at 11:30 a.m. ET.Live and archived audio webcasts will be available on the company's website at investors.solventum.com. About SolventumAt Solventum, we enable better, smarter, safer healthcare to improve lives. As a new company with a
ST. PAUL, Minn., Aug. 20, 2024 /PRNewswire/ -- Solventum (NYSE:SOLV), formerly 3M Health Care, today announced that its autonomous coding solution has received Toolbox designation from Epic in the Fully Autonomous Coding category. Toolbox is a designation for products using established integration technologies in specific categories that meet Epic's recommended connection pattern. Solventum's ambient clinical documentation solution can be found in the Connection Hub on Epic Showroom. By connecting workflows between clinicians and coders, this integrated approach enables comple
Separation activities and business continuity on trackReported sales increased 0.2% to $2.081 billion; organic sales increased 1.3%GAAP Earnings Per Share (EPS) of $0.51; adjusted EPS1 of $1.56Generated $355 million in cash from operations; free cash flow1 of $297 millionRaises full-year 2024 organic sales growth and adjusted EPS guidanceST. PAUL, Minn., Aug. 8, 2024 /PRNewswire/ -- Solventum (NYSE:SOLV) today reported financial results as a stand-alone company for the second quarter ended June 30, 2024. "As we continue to execute a complex transformation, we're encouraged by
ST. PAUL, Minn., July 16, 2024 /PRNewswire/ -- Solventum (NYSE:SOLV) will release its second quarter 2024 financial results on Thursday, August 8, 2024 after the U.S. financial markets close. The company will also host a conference call that day at 4:30 p.m. Eastern Time to discuss its second quarter financial results and provide an update on its business. The conference call can be accessed via audio webcast at investors.solventum.com or by dialing (800) 715-9871 within the U.S. or +1 (646) 307-1963 for international callers, using the conference ID 6342275. A replay of the w
ST. PAUL, Minn., July 2, 2024 /PRNewswire/ -- Solventum today announced that U.S. News & World Report is expanding its use of Solventum's 3M™ Ambulatory Potentially Preventable Complications (AM-PPCs) software in the analysis of its 2024-2025 Best Hospitals rankings. "We are excited to support U.S. News & World Report as they expand the use of Solventum's AM-PPCs software into the Ear, Nose & Throat specialty ranking, the Prostate Cancer Surgery rating and the new Gynecological Cancer Surgery rating," said Dr. Sandeep Wadhwa, global chief medical officer, Health Information Sy
NYSE issuers raise $12 billion as IPO activity builds momentum Welcomes 7 of the 10 largest U.S. transactions The Big Board continues to drive exchange transfers The New York Stock Exchange, part of Intercontinental Exchange, Inc. (NYSE:ICE), a leading global provider of technology and data, today reported an industry-leading $12 billion in IPO proceeds for the first half of 2024, setting the pace globally as IPO activity regained momentum compared to the prior two years. The NYSE listed 7 of the 10 largest U.S. transactions so far this year, including the two largest IPOs: Viking Holdings (NYSE:VIK) and Amer Sports (NYSE:AS). The exchange also led the re-emergence of technology IPO
ST. PAUL, Minn., June 24, 2024 /PRNewswire/ -- Solventum (NYSE:SOLV), [formerly 3M Health Care] today announced a new artificial intelligence (AI)-driven payment integrity and revenue cycle solution, Solventum™ Revenue Integrity System. In collaboration with Sift Healthcare, this solution is designed to help health systems not only reduce potential denials but prevent them and ensure timely and accurate payer reimbursement. With tight margins and reduced resources, claim denials from payers are a persistent challenge across the healthcare industry, leading to significant rev
ST. PAUL, Minn., June 7, 2024 /PRNewswire/ -- Solventum (NYSE:SOLV) has been notified that TRC Capital Investment Corporation ("TRC") made an unsolicited "mini-tender offer" to purchase up to 2,000,000 shares of the company's common stock at $59.15 per share and decreased the offer price on June 6, 2024, to $55.00 per share. The closing stock price of Solventum's common stock on June 6, 2024 was $55.05. As of the date of this press release, Solventum expresses no opinion and is neutral toward TRC's tender offer but cautions stockholders to monitor the trading price of the Solv
UPS: -9% | United Parcel Service Q2 2024 Adj EPS $1.79 Misses $1.99 Estimate, Sales $21.820B Miss $22.183B Estimate SOLV: 6.9% | Solventum shares are trading higher following a report suggesting Trian has built a stake in the company. TUSK: 57% | Mammoth Energy Services shares are trading higher after the company announced its subsidiary, Cobra Acquisitions, entered into a release and settlement agreement with the Puerto Rico Electric Power Authority.
- Bloomberg
5 analysts have shared their evaluations of Solventum (NYSE:SOLV) during the recent three months, expressing a mix of bullish and bearish perspectives. In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 0 3 0 2 Last 30D 0 0 1 0 0 1M Ago 0 0 1 0 1 2M Ago 0 0 0 0 1 3M Ago 0 0 1 0 0 Insights from analysts' 12-month price targets are revealed, presenting an average target of $57.4, a high estimate of $70.00, and a low estimate of $48.00. Experiencing a 11.24% decline, the current averag
Morgan Stanley analyst Patrick Wood maintains Solventum (NYSE:SOLV) with a Equal-Weight and lowers the price target from $70 to $55.
Goldman Sachs analyst David Roman maintains Solventum (NYSE:SOLV) with a Sell and lowers the price target from $54 to $48.
Ratings for Solventum (NYSE:SOLV) were provided by 5 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 0 4 0 1 Last 30D 0 0 1 0 0 1M Ago 0 0 0 0 1 2M Ago 0 0 1 0 0 3M Ago 0 0 2 0 0 Analysts have recently evaluated Solventum and provided 12-month price targets. The average target is $64.6, accompanied by a high estimate of $70.00 and a low estimate of $54.00. This current average represents a 7.
B of A Securities analyst Travis Steed maintains Solventum (NYSE:SOLV) with a Neutral and lowers the price target from $70 to $60.